Background: ACRIN 6668/RTOG 0235 evaluated the prognostic value of positron emission tomography with
article treatment plan for a large portion of patients being considered for definitive chemoradiotherapy (3) . For patients being treated with definitive radiotherapy, PET can aid with target delineation. (4) ACRIN 6668/RTOG 0235 was a prospective, multi-institutional trial performed to evaluate the prognostic value of pre-and post-treatment PET imaging for patients treated with definitive chemoradiotherapy for stage III and medically inoperable stage II NSCLC (ClinicalTrials.gov identifier: NCT00083083) (5) . PET findings were quantified as peak and maximum standardized uptake value (SUV peak and SUV max , respectively), and the primary study objective was to examine the relationship between posttreatment SUV peak and overall survival. Volume-based PET measures were not generated as part of the original analysis. In this companion secondary analysis of ACRIN 6668/RTOG 0235, we evaluated the ability of pretreatment volumetric PET measures to predict clinical outcomes, including both overall survival and locoregional disease control.
Methods

Study Design
The study design of ACRIN 6668/RTOG 0235 has been described previously (5) . Briefly, eligible patients had stage III NSCLC or inoperable stage II NSCLC (using 1997 AJCC staging criteria [6] ), had a Zubrod performance status of 0-1, and were deemed candidates for definitive concurrent chemoradiotherapy. Treatment consisted of thoracic radiotherapy to a dose of at least 60 Gy with concurrent, platinum-based doublet chemotherapy. Maintenance chemotherapy was allowed. All patients underwent FDG-PET or FDG-PET/CT on a scanner qualified by the American College of Radiology Imaging Core Laboratory (7) prior to the initiation of chemoradiotherapy as well as 12 to 16 weeks after completion of radiotherapy on the same scanner. The intended sample size was 250 participants, including at least 75 with stage IIB/IIIA and at least 75 with stage IIIB disease. Patients consented to the original prospective study, which was approved by the local institutional review boards of each participating institution.
Image Analysis
All available pretreatment PET images were collected centrally and transferred to a commercially available software package (MIMvista Version 4.2.2, MIMvista Corp., Cleveland, OH). Using a semiautomatic gradient-based contouring algorithm ("PET Edge"), all visible thoracic hypermetabolic lesions were contoured for each patient by a single observer (NO) who was blinded to all clinical outcomes. No quantitative criterion (eg, SUV max ) was used to identify hypermetabolic lesions at this point. Contours were verified by a second observer (MWW). Lesions were coded as pulmonary tumor (T) or regional lymph node (N). Lymph nodes were further classified by nodal station, as described by Chapet et al. (8) . For each patient and scan, we extracted the following metrics describing the union of all contoured lesions: SUV max , metabolic tumor volume (MTV), and total glycolytic activity (TGA, defined as mean SUV multiplied by MTV). We also recorded the number of discrete hypermetabolic lesions that were contoured on each scan.
Statistical Methods
Clinical endpoints for this analysis were all-cause mortality and in-field disease progression, which was scored by the treating physicians. Survival time and locoregional failure time were defined as the interval from study registration to event occurrence or patient censoring. In examining time to locoregional failure, patients who died prior to recording a locoregional failure were treated as censored. Because imaging studies and clinical outcomes were not uniformly available, sample sizes varied between analyses. All analyses were restricted to patients with stage III disease (96.2% of eligible patients).
Univariate Cox proportional hazards regression modeling was utilized to evaluate pretreatment PET metrics (SUV max , MTV, TGA, number of lesions) as predictors of locoregional disease control and overall survival. Multivariable Cox proportional hazards regression models including PET metrics as well as clinical variables (sex, age, performance status, and clinical stage) were used to identify independent predictors of locoregional control and overall survival. Model diagnostics related to the Cox model were assessed using scaled Schoenfeld residuals (9) . In cases where there was evidence of nonproportional hazards, timedependent covariables were added to the model through an appropriate interaction with time. TGA was excluded from the multivariable models presented herein, because it was highly correlated with MTV (Spearman correlation = 0.90, P < .001), which is more easily calculated. For comparison, we generated a second set of multivariable models using TGA in place of MTV. The performances of the two sets of models were compared using Akaike information criterion (AIC) and Bayesian information criterion (BIC) (9) .
Kaplan-Meier survival curves were generated to depict the association between MTV and each clinical outcome. One set of curves depicted outcomes after sorting subjects into tertiles based on MTV.A second set of curves was generated after dividing patients into two groups based on the optimal MTV threshold as determined by recursive partitioning in a conditional inference framework, with the stipulation that at least 5% of patients must fall on either side of the optimal threshold (10). Log-rank testing was performed to compare outcomes between groups.
A Bonferroni correction was used to account for multiple testing. Since there were two clinical outcomes of interest, a P value threshold of .025 was used to declare statistical significance. All statistical tests were two-sided. All statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC), R v3.1.0 (R project, http://www.r-project.org), or Matlab (The Mathworks, Natick, MA).
Results
Patient Characteristics
Of 250 accrued patients, 16 were ineligible. Characteristics of the entire study population have been described previously (5) . Because outcomes and imaging data were not available for all subjects, slightly different patient subsets were utilized for analyses of locoregional disease control and overall survival. Characteristics of the patient subgroups are summarized in Table 1 . 
Pretreatment PET and Overall Survival
At the time of database locking, median survival time after study registration was 19.9 months, and 159 patients (74.3%) had died. Univariate Cox proportional hazards testing revealed that pretreatment MTV (HR = 1.04 per 10 cm 3 increase, 95% CI = 1.03 to 1.06, P < .001) and pretreatment TGA (HR = 1.33 per natural log increase, 95% CI = 1.15 to 1.54, P < .001) were statistically significant predictors of mortality, while SUV max was not prognostic (HR = 1.01, 95% CI = 0.99 to 1.03, P = .38). Median survival was 29.7 months for patients in the lowest MTV tertile, 21.2 months for subjects in the middle tertile (>39.2 cm 3 and ≤89.8 cm 3 ), and 13.6 months for those in the highest tertile (logrank P < .001) (Figure 1 ). The optimal single MTV cutpoint was 95.4 cm 3 . Median survival for patients with MTV less than or equal to 95.4 cm 3 was 23.6 months, and median survival was 13.4 months for subjects with higher MTVs (log-rank P < .001) (Figure 1) .
Multivariable Cox proportional hazards modeling results are presented in Table 2 . Pretreatment MTV was independently associated with overall survival (HR = 1.04 per 10 cm 3 increase, 95% CI = 1.03 to 1.06, P < .001). Poor performance status and increasing age were also independently associated with increased mortality risk. A time dependent covariable for performance status was included in the final model. Replacing MTV with TGA in the multivariable model altered the AIC and BIC values by 1%, slightly favoring the MTV model.
Pretreatment PET and Locoregional Control
Nine of the 233 eligible patients who underwent the pretreatment PET scan had stage IIB disease, 29 did not have followup data regarding locoregional failure, and six had imaging that could not be evaluated. For the remaining 189 evaluable patients, median locoregional control time was 25.3 months after study registration, and 79 patients (41.8%) experienced locoregional failure. Univariate Cox proportional hazards testing revealed that both pretreatment MTV and pretreatment TGA were statistically significant predictors of locoregional failure, while SUV max was not prognostic (HR = 1.02, 95% CI = 0.99 to 1.04, P = .26). Proportional hazards assumptions were violated in the univariate models for MTV and TGA. After including a time-varying covariable via an interaction with an appropriate transformation of time, high MTV was associated with increased risk of locoregional failure at baseline (HR = 1.15 per 10 cm 3 increase, 95% CI = 1.08 to 1.22, P < .001) and at six months (HR = 1.04 per 10 cm 3 increase, 95% CI = 1.02 to 1.06, P < .001), but not at 12 months or later time points (data not shown). Median time to locoregional failure was 30.5 months for patients in the lowest MTV tertile, not reached for subjects in the middle tertile (>39.2 cm 3 and ≤89.8 cm 3 ), and 15.8 months for those in the highest tertile (log-rank P = 0.12) (Figure 2 ). The optimal single MTV cutpoint was 95.4 cm 3 . Median time to locoregional failure for patients with MTV less than or equal to 95.4 cm 3 was 38.2 months, compared with 14.5 months for subjects with higher MTVs (log-rank P = .01) (Figure 2 ).
In the multivariable Cox proportional hazards model (Table 3) Patients are dichotomized using the identified optimal cutpoint. All statistical tests were two-sided. For each strata, the number of patients still at risk is listed below the curves. CI = confidence interval; MTV = metabolic tumor volume. with locoregional failure. Again, there was evidence of nonproportional hazards for MTV, implying that the association with locoregional control diminished over time. A time-dependent covariable for MTV was therefore included in the final multivariable model. High MTV demonstrated a statistically significant association with increased risk of locoregional failure at baseline (HR = 1.16 per 10 cm 3 increase, 95% CI = 1.08 to 1.23, P < .001) and at six months (HR = 1.05 per 10 cm 3 increase, 95% CI = 1.02 to 1.07, P < .001), but not at 12 months or later time points. Poor performance status was also associated with increased risk of locoregional failure, although this effect was also found to diminish over time. Replacing MTV with TGA in the multivariable model altered the AIC and BIC values by 1%, again slightly in favor of the MTV model.
Discussion
ACRIN 6668/RTOG 0235 is the largest prospective trial to date evaluating the prognostic value of quantitative PET findings in locally advanced NSCLC patients treated with chemoradiotherapy. The primary analysis of this study revealed that elevated post-treatment SUV max confers a poor prognosis with respect to article overall survival. In this complementary secondary analysis, we have demonstrated that, prior to treatment, pretreatment MTV serves as an independent predictor of both locoregional control and overall survival.
Previous efforts have demonstrated that a large tumor burden confers a poor prognosis in locally advanced NSCLC. Analyses of several datasets have demonstrated that gross tumor volume (GTV) defined on CT is a powerful prognostic factor for inoperable NSCLC patients treated with definitive RT and may trump clinical staging as a predictor of overall survival (11) (12) (13) (14) . More recent retrospective analyses have suggested that MTV measured on FDG-PET can serve as a prognostic factor for NSCLC patients (15) (16) (17) . The cohorts evaluated in those reports, however, were heterogeneous with respect to disease stage and treatment. Our findings build upon those results using a large, prospectively collected dataset of images acquired using a standardized protocol on ACRIN-qualified scanners to demonstrate the prognostic significance of disease burden in stage III 
B)
Patients are dichotomized using the identified optimal cutpoint. All statistical tests were two-sided. For each strata, the number of patients still at risk is listed below the curves. CI = confidence interval; MTV = metabolic tumor volume; NA = not applicable, which signifies that the corresponding quantity cannot be estimated. article NSCLC patients who are staged with PET and treated with concurrent, 3D-planned chemoradiotherapy. Our study is not without limitations. We were unable to evaluate GTV as a prognostic factor in this dataset, as RT plans were not collected as part of the protocol, and not all patients underwent combined PET/CT. Based on our clinical experience and published findings (18), we recognize that GTV and MTV are highly correlated. We expect that the two measures would likely perform similarly as prognostic factors, though this is impossible to prove in the present study. However, we favor MTV because it can be calculated very quickly using semiautomatic contouring tools and can minimize interobserver variability, which is known to be an issue in CT-based target delineation (19, 20) . PET may be especially valuable for measuring viable tumor volume in cases where lesions are adjacent to atelectatic lung tissue (21).
We unexpectedly found that high MTV was associated with increased risk of locoregional disease progression only during the first year of follow-up and not at later time points. This is a novel finding. It may depict a true biologic effect or represent an artifact of the difficulties clinicians face when assessing locoregional control in this patient population. Evolving treatmentrelated radiographic changes could have been mistaken for disease recurrence in some cases. Second primary lung tumors ocurring in long-term follow-up could also be scored as disease progression. Each of these factors might cloud our ability to identify predictors of true lococregional recurrences following chemoradiotherapy.
In this report, we tested composite values for SUV max , MTV, and TGA across all visualized hypermetabolic lesions as predictors of clinical outcomes. We also assessed whether using separate tumor and lymph node measures (eg, MTV tumor , MTV nodal ) provided additional prognostic information. Univariate and multivariable testing revealed no evidence that outcome prediction models were improved when primary tumor and nodal stations were evaluated separately (data not shown).
This analysis was performed using traditional approaches for modeling survival outcomes. Several more advanced statistical methods for evaluating prognostic markers have been developed. These can involve the use of receiver operating characteristic (ROC) curves and decision analyses, ideally performed in training and validation sets (22) . A natural future step would be to examine the ACRIN 6668/RTOG 0235 dataset using those techniques.
While the results of this study may be used to identify stage III NSCLC patients with relatively favorable and poor prognoses, we acknowledge that these findings will not directly lead to changes in the management of this patient population. We believe, however, that findings from this analysis may guide the design of future clinical trials for this patient population. Previous and current cooperative group studies typically stratify patients by clinical stage (eg, IIIA vs IIIB). We suggest that future studies instead use a volumetric measure of disease burden such as MTV as a stratification factor. We hypothesize that selective intensification of local therapy may benefit those patients with high-volume disease, who are at increased risk for early local disease progression.
In conclusion, pretreatment tumor burden measured on PET is a predictor of clinical outcomes for stage III NSCLC patients treated with chemoradiotherapy. Quantitative PET measures may serve as stratification factors in clinical trials for this patient population and may help to guide novel trial designs. 
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